Pfizer Agrees To Postpone Drug Price Hikes After Trump Tweet
The pharmaceutical company says it will delay price increases that went into effect on July 1. The move follows pressure from President Trump.
Pharmaceuticals
Scientists Find New Tricks For Old Drugs
Researchers are looking to redeploy drugs used for years to treat cholesterol and high blood pressure as remedies for influenza and Ebola.
Opioid-Makers Cut Back On Marketing Payments To Doctors
ProPublica found that drugmakers spent less to market opioids to doctors in 2016 than in prior years. Studies have shown that payments to doctors are linked to more prescriptions for the drugs.
What Can Cancer Specialists Learn From Patients Who Beat All The Odds?
A Harvard Medical School project aims to become the first national registry for exceedingly rare cancer patients who respond mysteriously well to treatments that failed to help others.
'Cutting Edge' Program For Children With Autism And ADHD Rests On Razor-Thin Evidence
With 113 locations in the U.S., Brain Balance says its drug-free approach has helped tens of thousands of children. But experts say there's insufficient proof of its effectiveness.
Massachusetts Sues OxyContin Maker Purdue Pharma, Saying It 'Peddled Falsehoods'
The civil lawsuit is just one of many the opioid drug manufacturer now faces — but the complaint filed Tuesday adds an unusual wrinkle: It also singles out the Sackler family, which owns Purdue.
Right To Try Act Poses Big Challenge For FDA
Legislation that would give terminally ill people a direct path to get experimental treatments raises questions about how the Food and Drug Administration would safeguard patients.
New Type Of Drug To Prevent Migraines Heads To Market
An antibody-based drug reduces the frequency of migraine headaches, according to data reviewed by the Food and Drug Administration. The agency approved Aimovig, priced at about $6,900 a year.
How A Drugmaker Gamed The System To Keep Generic Competition Away
Celgene Corp. has thwarted rival drugmakers eager to make cheaper versions of medicines for a form of blood cancer. Now administration officials are criticizing practices they say hold generics back.
Trump Administration's 3 Biggest Ideas For Lowering Drug Prices
After criticism that the administration's blueprint for drug prices was vague, the secretary of health and human services zeroed in on actions that he said need only his signature.